IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
Jun RenP Anversa

Abstract

IGF-I rescues diabetic heart defects and oxidative stress, although the underlying mechanism of action remains poorly understood. This study was designed to delineate the beneficial effects of IGF-I with a focus on RhoA, Akt, and eNOS coupling. Echocardiography was performed in normal or diabetic Friend Virus-B type (FVB) and IGF-I transgenic mice. Cardiomyocyte contractile properties were evaluated using peak shortening (PS), time-to-90% relengthening (TR90), and intracellular Ca2+ rise and decay. Diabetes reduced fraction shortening, PS, and intracellular Ca2+; it increased chamber size, prolonged TR90, and intracellular Ca2+ decay. Levels of RhoA mRNA, active RhoA, and O2(-) were elevated, whereas nitric oxide (NO) levels were reduced in diabetes. Diabetes-induced O2(-) accumulation was ablated by the NO synthase (NOS) inhibitor nitro-L-arginine methyl ester (L-NAME), indicating endothelial NOS (eNOS) uncoupling, all of which except heart size were negated by IGF-I. The IGF-I-elicited beneficial effects were mimicked by the Rho kinase inhibitor Y27632 and BH4. Diabetes depressed expression of Kv1.2 and dihydrofolate reductase (DHFR), increased beta-myosin heavy-chain expression, stimulated p38 MAPK, and reduced levels of tot...Continue Reading

References

Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·J S PollockF Murad
Sep 1, 1986·The Journal of Clinical Endocrinology and Metabolism·K Tan, R C Baxter
Nov 1, 1995·The American Journal of Physiology·P A HofmannK F Gannaway
May 1, 1995·Circulation Research·J M GardinL A Leinwand
Feb 1, 1994·Cardiovascular Drugs and Therapy·F S Fein, E H Sonnenblick
Apr 1, 1994·Circulation Research·Y ShimoniW Giles
Jan 13, 1997·Biochemical and Biophysical Research Communications·N NiiroH Kanaide
Jun 26, 1999·Acta Physiologica Scandinavica·S ChattouD Feuvray
Sep 15, 2001·American Journal of Physiology. Heart and Circulatory Physiology·A NishiyamaM M Tamkun
Aug 15, 2002·Cardiovascular Research·Naohiko KobayashiHiroaki Matsuoka
Sep 10, 2002·American Journal of Physiology. Endocrinology and Metabolism·Faye L NorbyJun Ren
Jan 14, 2003·The Journal of Biological Chemistry·Vincent SauzeauPierre Pacaud
Jan 18, 2003·American Journal of Physiology. Endocrinology and Metabolism·Jinhong DuanJun Ren
Apr 10, 2004·American Journal of Physiology. Heart and Circulatory Physiology·James R Sowers
Jun 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Trinity J BivalacquaPhilip J Kadowitz
Aug 12, 2004·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Nicholas S AberleJun Ren
Dec 21, 2004·Journal of the American College of Cardiology·Maike Krenz, Jeffrey Robbins
Feb 18, 2005·Acta Pharmacologica Sinica·Jun Ren, Cindy X Fang
Apr 6, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xiaoping YangJun Ren
Apr 13, 2007·Cardiovascular Research·Guorong LinKathleen M MacLeod

❮ Previous
Next ❯

Citations

May 4, 2013·Journal of Bioenergetics and Biomembranes·Nihal OzturkSemir Ozdemir
Jul 12, 2011·Acta Pharmacologica Sinica·Hong ZhouRui-ying Wang
Aug 9, 2012·Antioxidants & Redox Signaling·Ricardo CarnicerDavid A Kass
Mar 28, 2012·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Zoltan Ungvari, Anna Csiszar
Apr 2, 2009·American Journal of Physiology. Endocrinology and Metabolism·Lu TieAlex F Chen
Aug 7, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Hesham SolimanKathleen M MacLeod
Oct 7, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Irina A IonovaGalen M Pieper
Apr 14, 2012·Circulation Research·Luigi FontanaValter D Longo
Apr 14, 2012·Circulation Research·Brian J North, David A Sinclair
Dec 4, 2013·Antioxidants & Redox Signaling·Jennifer K BendallMark J Crabtree
Aug 26, 2014·Nitric Oxide : Biology and Chemistry·Sanskriti KhannaMadhu Khullar
Mar 1, 2012·Vascular Pharmacology·Nathan D Roe, Jun Ren
May 10, 2011·Nitric Oxide : Biology and Chemistry·Mark J Crabtree, Keith M Channon
Oct 6, 2009·Journal of Molecular and Cellular Cardiology·Mark J Crabtree, Keith M Channon
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Hong Zhou, Yongjun Li
Jan 26, 2012·Hypertension·Susan A Marsh, Amy J Davidoff
Oct 5, 2018·American Journal of Physiology. Gastrointestinal and Liver Physiology·Pandu R GangulaChethan Sampath
Jun 15, 2010·American Journal of Physiology. Heart and Circulatory Physiology·C H LeoO L Woodman
Feb 14, 2018·Cardiovascular Endocrinology & Metabolism·Gerardo Rodriguez-Araujo, Hironori Nakagami
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Nomy Levin-IainaItamar Raz
May 31, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Katsuhiko NoguchiMasato Tsutsui
Jan 28, 2016·Clinical Science·Sanghamitra SahooPatrick J Pagano
Mar 7, 2020·Frontiers in Cardiovascular Medicine·Nina Kaludercic, Fabio Di Lisa
Nov 17, 2016·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Cheng Yu WangDongyuan Xu
Jul 20, 2021·Frontiers in Medicine·Teresa SalvatoreFerdinando Carlo Sasso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.